000186239 001__ 186239
000186239 005__ 20240229145739.0
000186239 0247_ $$2doi$$a10.3390/cancers14235865
000186239 0247_ $$2pmid$$apmid:36497348
000186239 0247_ $$2altmetric$$aaltmetric:139622766
000186239 037__ $$aDKFZ-2022-03036
000186239 041__ $$aEnglish
000186239 082__ $$a610
000186239 1001_ $$aWickert, Ricarda$$b0
000186239 245__ $$aRadiotherapy with Helium Ions Has the Potential to Improve Both Endocrine and Neurocognitive Outcome in Pediatric Patients with Ependymoma.
000186239 260__ $$aBasel$$bMDPI$$c2022
000186239 3367_ $$2DRIVER$$aarticle
000186239 3367_ $$2DataCite$$aOutput Types/Journal article
000186239 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1670858031_14295
000186239 3367_ $$2BibTeX$$aARTICLE
000186239 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186239 3367_ $$00$$2EndNote$$aJournal Article
000186239 520__ $$aEpendymomas are the third most-frequent pediatric brain tumors. To prevent local recurrence, the resection site should be irradiated. Compared to photon radiation treatment, proton therapy often achieves even better results regarding target coverage and organ-sparing. Due to their physical properties, helium ions could further reduce side effects, providing better protection of healthy tissue despite similar target coverage. In our in silico study, 15 pediatric ependymoma patients were considered. All patients underwent adjuvant radiotherapeutic treatment with active-scanned protons at Heidelberg Ion Beam Therapy Center (HIT). Both helium ion and highly conformal IMRT plans were calculated to evaluate the potential dosimetric advantage of ion beam therapy compared to the current state-of-the-art photon-based treatments. To estimate the potential clinical benefit of helium ions, normal tissue complication probabilities (NTCP) were calculated. Target coverage was comparable in all three modalities. As expected, the integral dose absorbed by healthy brain tissue could be significantly reduced with protons by up to -48% vs. IMRT. Even compared to actively scanned protons, relative dose reductions for critical neuronal structures of up to another -39% were achieved when using helium ions. The dose distribution of helium ions is significantly superior when compared to proton therapy and IMRT due to the improved sparing of OAR. In fact, previous studies could clearly demonstrate that the dosimetric advantage of protons translates into a measurable clinical benefit for pediatric patients with brain tumors. Given the dose-response relationship of critical organs at risk combined with NTCP calculation, the results of our study provide a strong rationale that the use of helium ions has the potential to even further reduce the risk for treatment related sequelae.
000186239 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000186239 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186239 650_7 $$2Other$$aIMRT
000186239 650_7 $$2Other$$aependymoma
000186239 650_7 $$2Other$$ahelium ions
000186239 650_7 $$2Other$$aion beam therapy
000186239 650_7 $$2Other$$alate sequelae
000186239 650_7 $$2Other$$anormal tissue complication probability
000186239 650_7 $$2Other$$apediatric brain tumors
000186239 650_7 $$2Other$$aprotons
000186239 7001_ $$aTessonnier, Thomas$$b1
000186239 7001_ $$aDeng, Maximilian$$b2
000186239 7001_ $$00000-0001-8463-514X$$aAdeberg, Sebastian$$b3
000186239 7001_ $$aSeidensaal, Katharina$$b4
000186239 7001_ $$aHoeltgen, Line$$b5
000186239 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b6$$udkfz
000186239 7001_ $$aHerfarth, Klaus$$b7
000186239 7001_ $$aHarrabi, Semi B$$b8
000186239 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14235865$$gVol. 14, no. 23, p. 5865 -$$n23$$p5865$$tCancers$$v14$$x2072-6694$$y2022
000186239 909CO $$ooai:inrepo02.dkfz.de:186239$$pVDB
000186239 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000186239 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000186239 9141_ $$y2022
000186239 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000186239 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000186239 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000186239 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-01-24T07:56:58Z
000186239 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-30
000186239 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-30
000186239 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000186239 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000186239 980__ $$ajournal
000186239 980__ $$aVDB
000186239 980__ $$aI:(DE-He78)E050-20160331
000186239 980__ $$aI:(DE-He78)HD01-20160331
000186239 980__ $$aUNRESTRICTED